Latest Breaking News On - Linnden communications - Page 4 : comparemela.com

Gain Therapeutics to Present at the Cambridge Healthtech Institute s 2nd Annual Neurodegeneration Targets Conference

Gain Therapeutics to Present at the Cambridge Healthtech Institute s 2nd Annual Neurodegeneration Targets Conference
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesMatthias alderSusan sharpeCompany annual report on formCambridge healthtech instituteGain therapeutics incExchange commission onExchange commissionLinnden communicationsMichaelj fox foundation for parkinson researchSilverstein foundation for parkinsonChief executive officerGain therapeuticsAnnual neurodegeneration targets conferenceDrug discoveryProgressive central nervous system

Gain Therapeutics Receives Approval to Commence Phase 1 Clinical Study of GT-02287 from the Human Research Ethics Committee (HREC) in Australia

First drug candidate identified with Gain’s proprietary computational drug discovery platform SEE-Tx® to enter clinical development phase BETHESDA, Md., Sept. 12, 2023 .

Matthias alderSusan sharpeInternational congressMovement disordersCompany annual report on formLinnden communicationsSilverstein foundation for parkinsonGain therapeutics incExchange commission onMichaelj fox foundation for parkinson researchBellberry human research ethics committeeExchange commissionChief executive officerSilverstein foundationGain therapeuticsPrivate securities litigation reform act

Gain Therapeutics (GANX) Presents New Preclinical Data Demonstrating a Reduction of Plasma Neurodegeneration Biomarker NfL after Administration of GT-02287

Gain Therapeutics (GANX) Presents New Preclinical Data Demonstrating a Reduction of Plasma Neurodegeneration Biomarker NfL after Administration of GT-02287
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Joanne taylorSusan sharpeMatthias alderMovement disordersResearch at gainDrug administrationInternational congressGain therapeutics incExchange commission onExchange commissionCompany annual report on formLinnden communicationsGain therapeuticsNeurofilament light chainSenior vice presidentLate breaker abstract

Gain Therapeutics Announces Second Quarter 2023 Financial Results and Business Update

HREC application submitted; on track to initiate Phase 1 clinical study of GT-02287 this year Acceptance of late breaking abstract for presentation at the International Congress of Parkinson’s Disease and Movement Disorders® in Copenhagen, Denmark BETHESDA, Md., Aug. 10, 2023 (GLOBE NEWSWIRE) Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today annou

Matthias alderSusan sharpeLinnden communicationsGain therapeutics incMovement disordersHuman research ethics committeeInternational congressExchange commissionCompany annual report on formExchange commission onChief executive officerLate breaker abstractMonths ended juneGain therapeuticsPrivate securities litigation reform actAnnual report

Oligomerix Publishes Preclinical Data on Novel Small Molecule Therapeutic in Development for Alzheimer s Disease and Rare Neurodegenerative Diseases

Oligomerix Publishes Preclinical Data on Novel Small Molecule Therapeutic in Development for Alzheimer s Disease and Rare Neurodegenerative Diseases
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

James moeMichelle linnWilliam erhardtJack pasiniPeter daviesLitwin zucker centerOligomerix incHead of development operations at oligomerixNational institutes of healthUllmann research centerNational institute onLinnden communicationsHead of development operationsHealth sciencesAlbert einstein college of medicineMemory disorders